News

Stephen Hurly, President and Chief Executive Officer of Eleven Biotherapeutics said: "Despite current therapies and surgical regimens, there remains a large unmet need for patients with recurring or

The project will use AbCellera’s single-cell screening platform to profile vaccine-specific human antibodies elicited by seasonal influenza vaccination and to generate large panels of human monoclonal antibodies with

Based in Albany of New York, AMRI provides drug discovery, development, cGMP manufacturing and aseptic fill and finish services to the pharmaceutical and biotechnology industries. Under the deal, the

JCAR017 is Juno’s investigative chimeric antigen receptor (CAR) T cell product candidate that targets CD19, a protein expressed on the surface of almost all B cell malignancies, and

The study dubbed APHINITY, compared Perjeta-based regimen with Herceptin and chemotherapy alone as an adjuvant therapy in 4,805 people with operable HER2-positive eBC. The Perjeta-based regimen is made up of

A search committee of the Board of Directors has been created and will begin conducting a thorough process to identify Mr. Hendrickson’s replacement. Mr. Hendrickson will remain with

The new cognitive solution will use real-world data and advanced analytical techniques to better understand the anticipated outcomes of several breast cancer treatments. Novartis expertise in breast cancer, along with IBM

Today’s decision makes Opdivo the first Immuno-Oncology agent approved in the European Union for the treatment of patients with this common type of bladder cancer. “Bladder cancer has

Under the terms of the agreement, Eloxx will become a wholly owned subsidiary of Sevion. Upon completion of the transaction, Sevion will change its name to Eloxx Pharmaceuticals,